Landmark stroke Trial Turns 30: A Look at Advances in Ischemic Stroke Treatment
Table of Contents
Three decades after a pivotal study on stroke treatment, advancements continue to improve patient outcomes.
It has been 30 years since the publication of the groundbreaking National Institute of Neurological Disorders and Stroke (NINDS) trial concerning tissue plasminogen activator for acute ischaemic stroke. The NINDS trial evaluated neurological and functional progress utilizing the National Institutes of Health Stroke Scale (NIHSS), Glasgow Coma Scale, modified Rankin Scale (mRS), and Barthel Index.1 Since the trial, the treatment of individuals wiht ischaemic stroke has seen rapid progress, including the more recent introduction of another thrombolytic agent, tenecteplase.
evolution of Stroke Management
The NINDS trial assessed neurological and functional improvements using the National Institutes of Health stroke Scale (NIHSS).
The landscape of stroke management has dramatically changed since the NINDS trial. The introduction of tenecteplase represents just one facet of this evolution, with ongoing research exploring new avenues for intervention and rehabilitation.
Looking Ahead
As research continues and new therapies emerge, the outlook for individuals affected by ischemic stroke continues to improve.
Frequently Asked Questions About Stroke
- What are the main types of stroke?
- The two main types of stroke are ischemic stroke (caused by a blocked artery) and hemorrhagic stroke (caused by bleeding in the brain).
- What are the common symptoms of stroke?
- Common symptoms include sudden numbness or weakness, confusion, trouble speaking, vision problems, and severe headache.
- How is stroke treated?
- Treatment depends on the type of stroke. Ischemic stroke may be treated with clot-busting drugs or mechanical clot removal. Hemorrhagic stroke may require surgery to stop the bleeding.
Amelia Gorman is a health reporter covering medical breakthroughs and public health trends.
